{
    "clinical_study": {
        "@rank": "112578", 
        "acronym": "OAB", 
        "arm_group": {
            "arm_group_label": "Biowave Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Demonstrate a response to stimulation of the posterior tibial nerve using the Biowave device\n      and a microneedle patch electrode in patients with overactive bladder symptoms.  The\n      investigators hypothesize that after at least 6 weekly treatments there will be modest\n      improvements in overactive bladder symptoms trending toward more improvement."
        }, 
        "brief_title": "Biowave Overactive Bladder Trial", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "detailed_description": {
            "textblock": "Women 18 years old and over with a score of equal to or greater than 4 on the OAB-q short\n      form for urgency and average daily urinary frequency equal to or greater than 10 times based\n      on a 3-day voiding diary plus other inclusion criteria will be reviewed for possible\n      enrollment in this study.  Outcomes measured include Global Response Assessment (GRA) for\n      overall bladder symptoms, a change in the 3-day voiding diary parameters and adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women >18 years of age\n\n          -  A score of > 4 on the OAB-q short form for urgency (question 1)\n\n          -  Average daily urinary frequency > 10 times based on a 3-day voiding diary\n\n          -  Self-reported bladder symptoms present > 3 months\n\n          -  Self-reported failed conservative care (i.e., dietary restriction, fluid restriction,\n             bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.)\n\n          -  Off all antimuscarinics for at least 2 weeks prior to enrollment\n\n          -  Capable of giving informed consent\n\n          -  Ambulatory and able to use a toilet independently, without difficulty\n\n          -  Capable and willing to follow all study-related procedures\n\n        Exclusion Criteria:\n\n          -  Pregnant as confirmed by urine pregnancy test, or plans to become pregnant during the\n             study period\n\n          -  Neurogenic bladder\n\n          -  Botox\u00ae use in bladder or pelvic floor muscles in the past year\n\n          -  Pacemakers or implantable defibrillators\n\n          -  Primary complaint of stress urinary incontinence\n\n          -  Current urinary tract infection (UTI)\n\n          -  Current vaginal infection\n\n          -  Current use of InterStim\u00ae\n\n          -  Current use of Bion\u00ae\n\n          -  Previously been treated with Percutaneous Tibial Nerve Stimulation (PTNS)\n\n          -  Use of investigational drug/device therapy within the past 4 weeks.\n\n          -  Participating or have participated within the past 4 weeks in any clinical\n             investigation involving or impacting gynecologic, urinary or renal function.\n\n          -  Deemed unsuitable for enrollment in study by the investigators based on subjects'\n             history or physical examination (including skin disorders at the treatment site or\n             peripheral neuropathy).\n\n          -  Subjects with nerve damage that would impact either percutaneous tibial nerve or\n             pelvic floor function."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848366", 
            "org_study_id": "2013-034"
        }, 
        "intervention": {
            "arm_group_label": "Biowave Treatment", 
            "intervention_name": "Biowave Treatment", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Frequency", 
            "urgency", 
            "incontinence"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "last_name": "Wendy Price, RN", 
                "phone": "248-551-3565"
            }, 
            "facility": {
                "address": {
                    "city": "Royal Oak", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48073"
                }, 
                "name": "William Beaumont Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Jason Gilleran, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Larry Sirls, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Biowave Overactive Bladder (OAB) Trial", 
        "overall_contact": {
            "last_name": "Wendy Price, RN", 
            "phone": "248-551-3565"
        }, 
        "overall_official": {
            "affiliation": "William Beaumont Hospitals", 
            "last_name": "Kenneth M Peters, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The GRA will be used to compare the proportion of subjects reporting 'moderately' or 'markedly improved' responses on the GRA after 12 weekly treatments.", 
            "measure": "Global Response Assessment (GRA)", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848366"
        }, 
        "responsible_party": {
            "investigator_affiliation": "William Beaumont Hospitals", 
            "investigator_full_name": "Kenneth Peters, MD", 
            "investigator_title": "Chairman, Department of Urology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "William Beaumont Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kenneth Peters, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}